Repurposing drugs to treat acute myeloid leukaemia
We desperately need new treatments for acute myeloid leukaemia (AML). Dr Karen Keeshan is studying whether existing drugs for solid tumours could be used to treat AML. This could quickly provide a new option for people living with the disease.
Acute myeloid leukaemia (AML) is a fast-growing form of blood cancer. However, the treatments available aren’t always able to control the disease. We desperately need to find new treatments for AML to improve people’s chances of survival.
Dr Karen Keeshan has been studying a molecule called TRIB2. She has found that blocking TRIB2 or removing it from leukaemia cells makes chemotherapy drugs more effective at treating the disease. While finding ways to stop TRIB2 working, Dr Keeshan has been studying drugs which block a family of proteins called the ERBB family. These drugs are currently used to treat solid tumours like lung cancer and breast cancer. She has discovered that these existing cancer drugs can kill AML cells, and that TRIB2 is destroyed during this process. In this project, Dr Keeshan will study in more detail how these drugs work, and the role that TRIB2 has in this. She will test these drugs on AML cells grown in the lab and in mice. She hopes to find out more about why these drugs lead to the destruction of TRIB2, and whether these drugs could be repurposed to treat AML.
Dr Keeshan’s work will reveal whether the ERBB-blocking drugs have potential as treatments for AML. Because these drugs are already being used, they could benefit people with AML sooner than creating brand-new drugs. She hopes that her work could rapidly lead to clinical trials of these drugs, which could give people with AML a better chance of survival.